Uno studio di fase 2 sull'efficacia e sulla sicurezza di GAL-101, soluzione oftalmica al 2% nell'atrofia geografica non foveale secondaria all'AMD non neovascolare (eDREAM)
Uno studio di fase 2, in doppio cieco, randomizzato, multicentrico, a gruppi paralleli, controllato con placebo per indagare l'efficacia e la sicurezza di GAL-101, soluzione oftalmica al 2%, in pazienti con atrofia geografica non foveale secondaria ad età non neovascolare. Degenerazione maculare correlata: studio EDREAM
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
In this study, if both eyes qualify for the study, the eye with the better BCVA will be defined as the study eye. If both eyes qualify for the study and have identical BCVA, then the eye with higher baseline peripheral retinal degenerations (PRD) will be defined as the study eye. If baseline PRD is identical, then the right eye (OD) will be defined as the study eye. Only the study eye will be dosed with the Investigation Medicinal Product (IMP).
During visits, patients will administer 3 applications of 1 drop of GAL-101 or a matching Placebo that does not contain the active pharmaceutical ingredient (API) at 5-minute intervals (i.e., 1st application, wait 5 minutes, 2nd application, wait 5 minutes, 3rd application), under the supervision of trained and authorized study personnel. In between visits, patients will be instructed to administer 2 applications of 1 drop at 5-minute intervals once a day.
The study will be comprised of a 12- to 24-month treatment period determined individually according to patients' overall placement in global study randomization. All patients will participate at least 12 months of treatment. The visit schedule includes the following: Screening visits (Visit 1a and 1b) for image capture and confirmation of study eligibility by a reading center; Baseline/Randomization/Day 1 (Visit 2); a phone call at 2 weeks; and on-treatment clinic visits for safety and efficacy evaluations at 1 month, 3 months, 6 months, 9 months, and 12 months. Patients will continue to attend on-treatment clinic visits at 3-month intervals after 12 months until the last patient randomized in the study has completed 12 months of study treatment.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Galimedix Inc. c/o Imperial CRS, MD
- Numero di telefono: +1 (301) 9179191
- Email: info@galimedix.com
Backup dei contatti dello studio
- Nome: Luciana Summo, PhD
- Email: info@galimedix.com
Luoghi di studio
-
-
-
Yerevan, Armenia, 0048
- Reclutamento
- Ophthalmological Center After S.V. Malayan
-
Contatto:
- Ani Babayan
- Numero di telefono: +37494909990
- Email: babayanani88@yahoo.com
-
Investigatore principale:
- Lilit Voskanyan, MD, PhD
-
-
-
-
-
Bordeaux, Francia, 33000
- Reclutamento
- Centre Rétine Gallien
-
Contatto:
- Manon Demeurs
- Numero di telefono: 33 (5) 56 11 32 25
- Email: arc@retinegallien.com
-
Investigatore principale:
- Eric Fourmaux, MD
-
Lyon, Francia, 69317
- Reclutamento
- Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon
-
Contatto:
- Roxane Bai
- Numero di telefono: +33 (0)4 26 73 27 02
- Email: roxane.bai@chu-lyon.fr
-
Investigatore principale:
- Laurent KODJIKIAN, MD
-
Marseille, Francia, 13008
- Reclutamento
- Centre Monticelli Paradis d'Ophtalmologie
-
Contatto:
- Agné Devin Dr.
- Numero di telefono: 049116 05 84
- Email: agne.retine@gmail.com
-
Investigatore principale:
- François Devin, MD
-
Paris, Francia, 75006
- Reclutamento
- Centre Ophtalmologique Odéon
-
Contatto:
- Sumeyye OZALTUN
- Email: ozalt.sumeyye@gmail.com
-
Contatto:
- Favard, MD
-
Investigatore principale:
- Catherine Favard, MD
-
Tours, Francia, 37540
- Reclutamento
- Centre médico-chirurgical de Touraine
-
Contatto:
- Sarah Van Herreweghe
- Numero di telefono: 33 (0)2 47 64 67 27
- Email: svanherreweghe6@gmail.com
-
Investigatore principale:
- Sam Razavi, MD
-
-
-
-
-
Tbilisi, Georgia, 0162
- Reclutamento
- Akhali Mzera Limited
-
Contatto:
- Revaz Bezarashvili
- Numero di telefono: (+995) 555 55 54 82
- Email: rezieye@gmail.com
-
Investigatore principale:
- Shalva Skhirtladze, MD
-
Tbilisi, Georgia, 0186
- Reclutamento
- Caucasus Medical Centre LLC
-
Contatto:
- Sopio Tsiklauri, MD
- Numero di telefono: (+995) 595 974 774
- Email: soffia01@yahoo.com
-
Investigatore principale:
- Mikheil Omiadze, MD, PhD
-
-
-
-
-
Bonn, Germania, 53127
- Reclutamento
- Universitäts-Augenklinik Bonn
-
Investigatore principale:
- Kristina Pfau, MD
-
Contatto:
- Joanna Czauderna Study Coordinator
- Numero di telefono: 0228 287-11493
- Email: Joanna.Czauderna@ukbonn.de
-
Freiburg im Breisgau, Germania, 79106
- Reclutamento
- Universitätsklinikum Freiburg Klinik für Augenheilkunde
-
Investigatore principale:
- Hansjuergen Agostini, MD
-
Contatto:
- Christine Kremer
- Numero di telefono: +49 761 270 40231
- Email: christine.kremer@uniklinik-freiburg.de
-
Hanover, Germania, 30625
- Reclutamento
- Medizinische Hochschule Hannover Augenklinik
-
Contatto:
- Irene Oluwatoba-Popoola
- Email: Oluwatoba-popoola.irene@mh-hannover.de
-
Investigatore principale:
- Ekaterina Sokolenko, MD
-
Neubrandenburg, Germania, 17036
- Reclutamento
- Dietrich Bonhoeffer Klinikum
-
Contatto:
- Ulrike Holland
- Numero di telefono: +49 395 775 13427
- Email: aug-st2@dbknb.de
-
Investigatore principale:
- Christian Brinkmann, MD
-
Tübingen, Germania, 72076
- Reclutamento
- Universitätsklinikum Tübingen, Department für Augenheilkunde.
-
Contatto:
- Angela Geiger
- Email: Felix.Reichel@med.uni-tuebingen.de
-
Investigatore principale:
- Felix Reichel, MD
-
Ulm, Germania, 89075
- Non ancora reclutamento
- UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde
-
Contatto:
- Julia Ciboci
- Email: Julia.Ciboci@uniklinik-ulm.de
-
Investigatore principale:
- Armin Wolf, MD
-
-
-
-
-
Kildare, Irlanda, W91 W535
- Reclutamento
- UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland
-
Investigatore principale:
- Eugene Ng, MD
-
Contatto:
- Hiella Akhundova
- Numero di telefono: +353 89 411 2119
- Email: hiella.a@ioes.ie
-
Waterford, Irlanda, X91 DH9W
- Reclutamento
- Institute of Eye Surgery (IOES Waterford)
-
Investigatore principale:
- Eugene Ng, MD
-
Contatto:
- Emmanuel Ankamah
- Numero di telefono: +353 89 411 2119
- Email: emmanuel.a@ioes.ie
-
-
-
-
-
Jerusalem, Israele, 9112001
- Reclutamento
- Hadassah Medical Center
-
Contatto:
- Michal Shpigel
- Numero di telefono: 972-54-4575921
- Email: smichal@hadassah.org.il
-
Investigatore principale:
- Tareq Jaouni, MD
-
Tel Aviv, Israele, 6423906
- Reclutamento
- Tel Aviv Medical Center
-
Contatto:
- Marina Gordon
- Numero di telefono: 972-3-6947371
- Email: marinago@tlvmc.gov.il
-
Investigatore principale:
- Omer Trivizki, MD
-
-
-
-
Milano
-
Milan, Milano, Italia, 20123
- Reclutamento
- Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe
-
Contatto:
- Mara Cattaneo Study Coordinator
- Email: mara.cattaneo@multimedica.it
-
Investigatore principale:
- Stela Vujosevic, MD
-
Milan, Milano, Italia, 20132
- Reclutamento
- Unità di Oculistica, IRCCS Ospedale San Raffaele
-
Contatto:
- Adelaide Pina Study Coordinator
- Numero di telefono: 0226433545
- Email: pina.adelaide@hsr.it
-
Investigatore principale:
- Francesco Bandello, MD
-
-
Roma
-
Roma, Roma, Italia, 00184
- Reclutamento
- UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
-
Contatto:
- Ilaria Casale, Dr
- Email: ilaria.casale@fondazionebietti.it
-
Investigatore principale:
- Mariacristina Parravanno, MD
-
-
-
-
California
-
Beverly Hills, California, Stati Uniti, 90211
- Reclutamento
- Retina-Vitreous Associates Medical Group
-
Investigatore principale:
- David Boyer, MD
-
Contatto:
- Rahul Araza
- Numero di telefono: 3 (310) 289-2478
- Email: raraza@laretina.com
-
Walnut Creek, California, Stati Uniti, 94598
- Reclutamento
- Bay Area Retina Associates
-
Investigatore principale:
- Roger Goldberg, MD
-
Contatto:
- Karrie Padilla
- Numero di telefono: 925-265-4146
- Email: kpadilla@bayarearetina.com
-
-
Maryland
-
Hagerstown, Maryland, Stati Uniti, 21740
- Sospeso
- Cumberland Valley Retina Consultants
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
≥55 years of age
-
Willing and able to provide written informed consent
-
Willing and able to comply with the study schedule and study assessments
-
Able to successfully administer ophthalmic solution or have an appropriate designee (e.g., family member, health care professional) who can administer ophthalmic solution
-
BCVA of ≥50 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (i.e., 20/100 Snellen equivalent). Criterion will be confirmed at Baseline
-
Refractive error between +3 and -6 diopters spherical equivalent in the study eye
-
Sufficiently clear ocular media and adequate pupillary dilation to permit quality fundus imaging of the study eye, in the opinion of the Investigator. Criterion will be confirmed at Baseline
-
Diagnosed with non-foveal GA secondary to non-neovascular AMD in the study eye, as confirmed by the reading center
- Well-delineated cumulative GA area between 1.25 and 12.0 mm2
- If GA is multifocal, at least 1 lesion ≥1.25 mm2
- GA lesions must be located outside a ≥100 µm radius from the center point of the fovea (i.e., this area must have intact retinal pigment epithelium [RPE] and outer retina)
- GA lesions must be located (partially or wholly) within a 2000 µm radius from the center point of the fovea
- GA lesions must be completely located within FAF imaging field (field 2 to 30-degree image centered on the fovea). GA lesion borders must be >300 µm from image edges
- GA lesions must be >300 µm from the optic disc and/or peripapillary atrophy
- Area of PRD must be cumulatively between 7.25 and 25.0 mm2
Exclusion Criteria:
-
Presence or history of choroidal neovascularization (CNV). Criterion will be confirmed at Baseline
-
History of laser therapy in the macular region, regardless of indication
-
History of herpes zoster
-
Ophthalmic disease or condition that requires or is likely to require surgery during the study period
-
GA with cumulative area <1.25 mm2
-
Any GA lesion within 100 µm radius from the center point of the fovea
-
Axial length >26 mm
-
Any ocular disease or condition other than non-neovascular AMD that may, in the opinion of the Investigator, interfere with study assessments, patient adherence to the study schedule, or interpretation of study data (e.g., epiretinal membrane, macular hole, glaucomatous optic neuropathy, etc.)
-
Intraocular surgery (including cataract extraction and crystalline lens replacement) within 3 months before Visit 1a or yttrium aluminum garnet (YAG) surgery within 2 months before Visit 1a, or planned either during the study period
-
Use of pegcetacoplan or avacincaptad pegol within 6 months before Visit 1a, or planned use during the study period
-
Use of any prescription or over-the-counter ophthalmic medication within 1 month before Visit 1a or planned use during the study period
-
Use of rigid contact lenses within 1 month before Visit 1a or planned use during the study period
Non-study Eye:
-
BCVA of <5 letters using ETDRS chart (i.e., 20/800 Snellen equivalent)
Either Eye:
-
History of uveitis
-
GA secondary to any condition other than non-neovascular AMD
-
History of active ocular infection or inflammation within 3 months before Visit 1a or Baseline. Criterion will be confirmed at Baseline
-
Underwent investigational treatment for AMD within 6 months before Visit 1a
General Exclusion Criteria:
-
History of therapeutic radiation to the cranium
-
Known allergy or hypersensitivity to the investigational medicinal product (IMP) or any of its excipients
-
History of malignant disease
-
Use of hydroxychloroquine within 1 month before Visit 1a, or planned use during the study period
-
Participated or plan to participate in any other IMP study within 1 month before Visit 1a or during the study period
-
Use of lutein >10 mg per day or zeaxanthin >2 mg per day within 1 month before Visit 1a, or planned use during the study period
-
Any medical condition (including mental), in the opinion of the Investigator, that could interfere with study assessments, patient adherence to the study schedule, or interpretation of study data
-
Screening laboratory values, in the opinion of the Investigator, that make the patient unsuitable for study participation
-
Pregnant, nursing, or planning a pregnancy during the study. Criterion will be confirmed at Baseline
-
Unwilling or unable to use an acceptable method of contraception throughout the study if a woman of childbearing potential (WOCBP) or if a sexual partner of a WOCBP
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: GAL-101 ophthalmic solution
Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval |
Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval |
|
Comparatore placebo: Placebo
Patient will apply daily 2 eye drops ofPlacebo at 5 minutes interval |
Patient will apply daily 2 eye drops of Placebo at 5 minutes interval |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.
Lasso di tempo: From baseline to last on-treatment visit (48 up to 96 weeks)
|
Comparison between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF). |
From baseline to last on-treatment visit (48 up to 96 weeks)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in photoreceptor degeneration (PRD) in eyes with GA
Lasso di tempo: From baseline to last on-treatment visit (48 up to 96 weeks)
|
Comparison between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT) |
From baseline to last on-treatment visit (48 up to 96 weeks)
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- GAL-101-C0201
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .